Intas Pharmaceuticals to Acquire Coherus BioSciences’ Udenyca Business (Biosimilar, Neulasta)
Shots:
- Intas Pharmaceuticals, through its US specialty division Accord BioPharma, has entered into an agreement to acquire Coherus’ Udenyca business (pegfilgrastim-cbqv), a biosimilar of Amgen’s Neulasta, to enhance Accord’s biosimilar product portfolio. Deal is expected to conclude in Q1’25
- Udenyca is indicated to reduce infection risk from febrile neutropenia in patients with non-myeloid malignancies, on myelosuppressive anti-cancer drugs , and to increase survival in those exposed to myelosuppressive radiation
- Udenyca is a leukocyte growth factor available as a prefilled syringe (PFS), autoinjector (AI) & on-body injector (OBI), ensuring patient’s choice & convenience
Ref: PRNewswire | Image: Intas Pharmaceuticals & Coherus BioSciences
Related News:- Xbrane Biopharma and Intas Pharmaceuticals Join Forces to Develop Biosimilar of Opdivo (Nivolumab)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
